ERBB2 and breast cancer: Ado-trastuzumab-emtansine (TDM-1), a second-generation ADC, showed improvement in overall survival in second- and third-line settings in metastatic HER2-positive breast cancer when compared to lapatinib and capecitabine, following the failure of trastuzumab and taxane [94].